Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
13 pending office actions • 13 clients • 13 examiners • 11 art units • 0 of 13 (0%) have an AI response strategy ready
Houston Beshining Law Office PLLC has 12 pending office actions in Biotechnology & Pharmaceuticals and 283 career applications. Its resolved allowance rate is 70.94%, with an average of 2.51 office actions per allowance.
The profile combines a current docket with historical prosecution measures in the same technical area. The allowance rate provides an outcome signal for resolved matters, while the office-action average points to the response burden associated with allowances. Practitioners evaluating this record should consider both measures rather than treating either one as a complete description of prosecution performance.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (23%) |
| §102 only | 1 (8%) |
| Double-patenting + other | 4 (31%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| SASAN, ARADHANA | 1 | 64.6% | +26.0% |
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18482835 | NOSE-TO-BRAIN DELIVERY FORMULATION OF NIMODIPINE, PREPARATION AND USE | FOWLER, ALAN JEROME | 21d |
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | HABTE, KAHSAY | 62d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785041 | NEODYMIUM-IRON-BORON MAGNET MATERIAL, RAW MATERIAL COMPOSITION PREPARATION METHOD THEREFOR AND USE THEREOF | O'KEEFE, SEAN P | 26d |
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | KWON, YONG SOK | — |
| 18796363 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | MCDOWELL, BRIAN E | — |
| 18729910 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | OTTON, ALICIA L | — |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | BREDEFELD, RACHAEL EVA | — |
| 18248867 | SUBLINGUAL FILM DOSAGE OF RASAGILINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WISTNER, SARAH CLINKSCALES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | KWON, YONG SOK | — |
| 18796363 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | MCDOWELL, BRIAN E | — |
| 18704441 | 5-SUBSTITUTED PYRIDINE-2(1H)-KETONE COMPOUND AND USE THEREOF | MOORE, SUSANNA | — |
| 18419536 | ORAL RETENTION DEVICE AND OSMOTIC PUMP TABLET, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SASAN, ARADHANA | — |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | BREDEFELD, RACHAEL EVA | — |
| 18254186 | SALT OF PYRROLOPYRIMIDINE COMPOUND, CRYSTALLINE FORM THEREOF, AND APPLICATION THEREOF | STOCKTON, LAURA LYNNE | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1625 | 1 |
| 1613 | 1 |
| 1699 | 1 |
| 3783 | 1 |
| 1691 | 1 |
| 3786 | 1 |
| 1626 | 1 |
| 1616 | 1 |
| 3799 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18862180 | FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 | Scibrunch Therapeutics Co., Ltd. | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | KWON, YONG SOK | 1613 | §112DP | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18796363 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | Fujian Akeylink Biotechnology Co., Ltd. | MCDOWELL, BRIAN E | §102§112Other | Non-Final OA | — | Pending | Aug 07, 2024 | |
| 18729910 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Center For Excellence In Molecular Cell Science, Chinese Academy Of Sciences | OTTON, ALICIA L | 1699 | §102§112 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18704441 | 5-SUBSTITUTED PYRIDINE-2(1H)-KETONE COMPOUND AND USE THEREOF | Jiangsu Kanion Pharmaceutical Co., Ltd. | MOORE, SUSANNA | 1624 | §112DP | Final Rejection | — | Pending | Apr 24, 2024 |
| 18419536 | ORAL RETENTION DEVICE AND OSMOTIC PUMP TABLET, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Wd Pharmaceutical Co., Ltd. | SASAN, ARADHANA | 3783 | §103§112DP | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18482835 | NOSE-TO-BRAIN DELIVERY FORMULATION OF NIMODIPINE, PREPARATION AND USE | Nasal-Phyto (Shanghai) Pharmaceutical Technology Co., Ltd. | FOWLER, ALAN JEROME | 1691 | §103 | Final Rejection | 21d | Pending | Oct 06, 2023 |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | BREDEFELD, RACHAEL EVA | 3786 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Breakthrough Pharmaceuticals Inc. | HABTE, KAHSAY | 1624 | §103 | Non-Final OA | 62d | Pending | Jul 31, 2023 |
| 18254186 | SALT OF PYRROLOPYRIMIDINE COMPOUND, CRYSTALLINE FORM THEREOF, AND APPLICATION THEREOF | Guangzhou Joyo Pharmatech Co., Ltd. | STOCKTON, LAURA LYNNE | 1626 | §102§112DP | Non-Final OA | — | Pending | May 24, 2023 |
| 18248867 | SUBLINGUAL FILM DOSAGE OF RASAGILINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Modern Pharmaceutical Engineering Research Center Co., Ltd. | WISTNER, SARAH CLINKSCALES | 1616 | §103§112 | Final Rejection | — | Pending | Apr 12, 2023 |
| 18005963 | BIONIC TISSUE STENT, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Sinobioprint (Shanghai) Biotech Ltd. | PELLEGRINO, BRIAN E | 3799 | §103 | Final Rejection | — | Pending | Jan 18, 2023 |
| 17785041 | NEODYMIUM-IRON-BORON MAGNET MATERIAL, RAW MATERIAL COMPOSITION PREPARATION METHOD THEREFOR AND USE THEREOF | Fujian Golden Dragon Rare-Earth Co., Ltd. | O'KEEFE, SEAN P | 1738 | §103§112 | Non-Final OA | 26d | Pending | Jun 13, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial70.9% of resolved applications prosecuted by Houston Beshining Law Office Pllc were allowed, across 283 applications in USPTO records.
2.51 office actions per allowed application on average.
13 pending office actions as of October 2026, for 13 clients, before 13 examiners in 11 art units.
